Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 7
Submit an article Journal homepage
1,572
Views
6
CrossRef citations to date
0
Altmetric
Articles

Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study

Guillermo Garcia-Maneroa Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3631-2482View further author information
ORCID Icon,
Vincent Ribragb Department of Hematology, Gustave Roussy, Villejuif, FranceView further author information
,
Yayan Zhangc Department of Medical Oncology, Merck & Co., Inc, Kenilworth, NJ, USAView further author information
,
Mohammed Farooquic Department of Medical Oncology, Merck & Co., Inc, Kenilworth, NJ, USAView further author information
,
Patricia Marinelloc Department of Medical Oncology, Merck & Co., Inc, Kenilworth, NJ, USAView further author information
&
B. Douglas Smithd Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USAView further author information
Pages 1660-1668 | Received 30 Sep 2021, Accepted 21 Jan 2022, Published online: 04 Mar 2022

References

  • Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19):1872–1885.
  • Hellström-Lindberg E, Tobiasson M, Greenberg P. Myelodysplastic syndromes: moving towards personalized management. Haematologica. 2020;105(7):1765–1779.
  • Mohammad AA. Myelodysplastic syndrome from theoretical review to clinical application view. Oncol Rev. 2018;12(2):397.
  • Sweeney MR, Applebaum KM, Arem H, et al. Medical conditions and modifiable risk factors for myelodysplastic syndrome: a systematic review. Cancer Epidemiol Biomarkers Prev. 2019;28(9):1502–1517.
  • National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): myelodysplatic syndromes (Version 3.2021). 2021. https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf
  • Gil-Perez A, Montalban-Bravo G. Management of myelodysplastic syndromes after failure of response to hypomethylating agents. Ther Adv Hematol. 2019;10:2040620719847059.
  • Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010;76(3):218–227.
  • Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987–1996.
  • Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116(16):3830–3834.
  • Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–3739.
  • Armand P, Kuruvilla J, Michot JM, et al. KEYNOTE-013 4-year follow-up of pembrolizumab in classical hodgkin lymphoma after brentuximab vedotin failure. Blood Adv. 2020;4(12):2617–2622.
  • Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134(1):22–29.
  • Chien KS, Borthakur G, Naqvi K, et al. Final results from a phase II study combining azacitidine and pembrolizumab in patients with higher-risk myelodysplastic syndrome after failure of hypomethylating agent therapy. Blood. 2020;136(Supplement 1):23–24.
  • Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280–1288.
  • Cheng P, Eksioglu EA, Chen X, et al. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes. Leukemia. 2019;33(8):2034–2046.
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
  • US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), version 4.0. 2009. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf
  • Bhatnagar B, Zandberg DP, Vannorsdall EJ, et al. Lack of response of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) to decitabine after failure of azacitidine. Blood. 2012;120(21):3858–3858.
  • Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153.
  • Ribrag V, Avigan DE, Green DJ, et al. Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013. Br J Haematol. 2019;186(3):e41–e44.
  • Zeidan AM, Stahl M, Komrokji R. Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opin Emerg Drugs. 2016;21(3):283–300.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.